含奥沙利铂与含顺铂方案介入治疗中晚期肝癌的疗效比较  

Comparison of the therapeutic effects for advanced hepatocellular carcinoma treated with transcath- eter arterial chemoembolization involved oxaliplatin or cisplatin

作　　者：胡筱[1] 马桂香[1] 蒋文慧[1] 张丽花[1] 丁雷[1] 吕燕青[1] 范明磊[1] 

机构地区：[1]江苏省宿迁市泗阳县人民医院肿瘤科,宿迁223700

出　　处：《中国肿瘤临床与康复》2014年第1期74-77,共4页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的评价含奥沙利铂与顺铂经导管化疗栓塞术治疗中晚期原发性肝癌的疗效及不良反应。方法将167例中晚期肝癌患者分为两组：A组79例患者用奥沙利铂100—150mg，B组88例患者用顺铂40—60mg。之后两组均给予氟尿嘧啶750～1000mg静脉缓慢推注，然后将阿霉素40mg混合超液化碘油7．5—20ml行化疗栓塞，化疗药物剂量视患者全身和肝功能情况略有调整。第二周期治疗后进行cT扫描评价近期疗效。结果奥沙利铂介入治疗组患者的近期疗效（总有效率及甲胎蛋白改变）及远期疗效与顺铂介入治疗组之间差异均无统计学意义（P〉0．05）。两组患者均未发生严重的不良反应，但奥沙利铂治疗组的患者发生消化道反应及转氨酶升高的比例比顺铂治疗组更低，差异有统计学意义（P〈0．05）。结论含奥沙利铂的经导管化疗栓塞术可能为治疗中晚期原发性肝癌的一种有效且不良反应更小的方案。Objective To assess the efficacy and safety of transcatheter arterial chemoembolization （TACE） based on oxaliplatin and cisplatin for middle-advanced hepatocellular carcinoma （HCC）. Methods 167 patients diagnosed as advanced HCC in our hospital were included in this study. They were divided into two groups ： TACE was based on oxaliplatin （ 100 - 150 mg） in Group A （ n = 79） or cisplatin （40 60 mg） in Group B（n =88）, followed by 5-Fu （750 -1000 mg） and mixture of doxorubicin （40 mg） and lipiodol. The dosage of each chemotherapy medicine was adjusted according to the patients＇ condition and liver function. Objective response rate （complete response and partial response） was evaluated by CT scans after the second cycle. Results There was not significant difference in objective response rate and overall survival between the two groups （ P 〉 0. 05 ）. Though no patients in both groups appeared serious adverse effects, gastrointestinal/hepatic symptoms occurred more often and serious in the cisplatin group compared with the oxaliplatin group （ P 〈 O. 05）. Conclusions TACE base on Oxaliplatin appears to be an effective treatment with low toxicity in patients with advanced HCC.

关 键 词：肝肿瘤 经导管化疗栓塞术 

分 类 号：R735.7[医药卫生—肿瘤]